GRF:BME
grifols
9,53 €
arrow_downward
-0,67%(-0,064) 1D
2 ოქტ, 17:36:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
9,57 €
High
9,71 €
Low
9,48 €
Mkt. cap
5,74 მლრდ.
Avg. vol.
1,13 მლნ.
Volume
969,03 ათ.
Dividend
2,44%
Quarterly dividend
0,06 €
Ex-dividend date
30 ივნ. 2026
P/E ratio
14,34
52-wk high
12,87 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 მლნ.
No. of employees
25 ათ.
Open
9,57 €
High
9,71 €
Low
9,48 €
Mkt. cap
5,74 მლრდ.
Avg. vol.
1,13 მლნ.
Volume
969,03 ათ.
Dividend
2,44%
Quarterly dividend
0,06 €
Ex-dividend date
30 ივნ. 2026
P/E ratio
14,34
52-wk high
12,87 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 მლნ.
No. of employees
25 ათ.
News stories
From web sources and news partners
Stock Titan
·
24 წუთის წინ
A NYSE notice covers Getty Images (OTC: GETY) common stock removal from listing and/or registration.
CryptoSlate
·
49 წუთის წინ
Evernorth's Nasdaq XRP treasury is approved, but its real buying power isn't the $300 million expected
Yahoo Finance
·
39 წუთის წინ
Synopsys Is the Nasdaq 100’s Top Stock Today. The Target Says It’s Not Done
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About grifols